

USP <800> Hazardous Drugs Assessment of Risk

Per Policy, these drugs are exempt from USP<800> handling requirements under normal circumstances. The following outlines must be followed.

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
A	abacavir (Ziagen) PO [UD ⇒ UD]	Non - Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: No 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: do not crush tablet 	
Exposure Risk: <i>low</i>		
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a 	
NIOSH Supplemental Information: <i>malignant tumors observed in male/female mice/rats; genotoxic in in vivo micronucleus tests</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

	anastrozole (Arimidex) PO [UD ⇒ UD]	Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> • Receiving from Distributor: Designated area/ CX gloves • Pharmacy Storage Area: Hazardous • Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes • Manipulation of Dosage Form: Done in Pharmacy • Special Manipulation for Administration: do not crush tablet 	
Exposure Risk: <i>low</i>		
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: n/a 	
NIOSH Supplemental Information: <i>N/A</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
B	bicalutamide (Casodex) PO [Bulk ⇒ Blister UD]	Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: Double CX gloves, gown 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Designated area/ CX gloves Pharmacy Storage Area: Hazardous Packaging/Reconstitution Location: Repacking area 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omnicell load: No 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Single CX gloves, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Signage on Patient Door Required: Yes Closed System Storage Device: Yes Manipulation of Dosage Form: Done in Pharmacy Special Manipulation for Administration: do not crush tablet 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- black bin, trace- yellow bin Disposal of Used PPE: yellow bin Spill management: n/a 	
Disposal / Spills		
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>Wash skin with soap and water. Minimize dust accumulation.</i>		

C	carBAMazepine (Carbatrol, TEGretol) PO [Bulk ⇒ Packager]	Non - Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: Single CX glove and gown 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: Repacking area 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omnicell load: No 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Signage on Patient Door Required: No Closed System Storage Device: No Manipulation of Dosage Form: Standard Special Manipulation for Administration: n/a 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposal of Used PPE: trash bin (inside plastic bag) Spill management: n/a 	
Disposal / Spills		
NIOSH Supplemental Information: <i>BBW for aplastic anemia, congenital malformations in offspring of mothers who took drug, rapid trans placental passage</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Minimal manipulation for dispensing. Does not require additional manipulation for administering. Risk associated when ingested.</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
cidofovir (Vistide) IV [n/a]		Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX gloves, gown, CSTD • Receiving from Distributor: Standard • Pharmacy Storage Area: IV CSTD Area • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room Required: Med Prep Area with Immediate Use Preparation standards • Omnicell load: No 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Double Bag; single CX gloves 	
Nursing: Storage / Admin. Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Double CX gloves, gown, CSTD • Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes • Manipulation of Dosage Form: n/a • Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: Manage like antineoplastic agents 	
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>NIOSH recommends PPE + CSTD for preparation. PPE + CSTD required for administration. Pregnancy Category C. MSHG recommends following NIOSH. Also notes, if cidofovir contacts the skin, wash membranes and flush thoroughly with water. Risks are related to systemic absorption.</i>		

clonazepam (Klonopin) PO [Bulk ⇒ Packager]		Reproductive Risk
Pharmacy: Receiving / Storage / Preparation Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX gloves, wash hands after handling • Receiving from Distributor: Standard • Pharmacy Storage Area: CSM • Packaging/Reconstitution Location: Repackaging area • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin. Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- RX Destroyer, packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a 	
NIOSH Supplemental Information: <i>Increased risk of congenital abnormalities when taken in first trimester</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Minimal manipulation for dispensing. Does not require additional manipulation for administering.</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
colchicine (Colcrys, Mitigare) PO [UD ⇒ UD]	Reproductive Risk
Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: Yes	
Transport	• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No Exposure Risk: • Manipulation of Dosage Form: Standard <i>low</i> • Special Manipulation for Administration: n/a	
Disposal / Spills	• Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a
NIOSH Supplemental Information: <i>published animal reproduction and development studies indicate it causes embryo-fetal toxicity, teratogenicity and altered postnatal development at exposures within or above the clinical therapeutic range</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

cycloSPORINE (Gengraf, Neoral, SandIMMUNE) PO [UD ⇒ UD]	Non - Antineoplastic
Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: No	
Transport	• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: • Handling/administration PPE Requirements: Single pair of CX approved gloves; Wash hands after handling Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: No Exposure Risk: • Closed System Storage Device: No <i>low</i> • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: do not open capsule	
Disposal / Spills	• Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a
NIOSH Supplemental Information: <i>IARC Group 1 carcinogen; NTP</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
D	dinoprostone (Cervidil, Prepidil, Prostin E2) SUPP [n/a]	Reproductive Risk
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Freezer Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omniceil load: No 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Double CX gloves, gown, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy Signage on Patient Door Required: No Closed System Storage Device: No Manipulation of Dosage Form: Standard Special Manipulation for Administration: Do not handle while pregnant 	
Exposure Risk: <i>low</i>		
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposal of Used PPE: yellow bin Spill management: n/a 	
NIOSH Supplemental Information: <i>Hazardous only for women in late pregnancy</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

dronedarone (Multaq) PO [UD ⇒ UD]		Reproductive Risk
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omniceil load: Yes 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Single CX gloves, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell Signage on Patient Door Required: No Closed System Storage Device: No Manipulation of Dosage Form: Standard Special Manipulation for Administration: Do not handle while pregnant or trying to get pregnant 	
Exposure Risk: <i>low</i>		
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposal of Used PPE: trash bin (inside plastic bag) Spill management: n/a 	
NIOSH Supplemental Information: <i>Teratogenic in laboratory studies at 1/2 MRHD</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
dutasteride (Avodart) PO [UD ⇒ UD]	Reproductive Risk
Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: Yes	
Transport	• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No Exposure Risk: • Manipulation of Dosage Form: Standard <i>low</i> • Special Manipulation for Administration:	
Disposal / Spills	• Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a
NIOSH Supplemental Information: <i>Women warned not to handle</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

E	erlotinib (Tarceva) PO [Bulk ⇒ Blister UD]	Antineoplastic
	Pharmacy: • Handling/preparation PPE Requirements: Double CX gloves, gown Receiving / Storage / Preparation • Receiving from Distributor: Designated area/ CX gloves • Pharmacy Storage Area: Hazardous • Packaging/Reconstitution Location: Repackaging area Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>low</i> • Omnicell load: No	
	Transport	• Transport (dose is placed inside a plastic sealable bag): Standard
	Nursing: • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes Exposure Risk: • Manipulation of Dosage Form: Done in Pharmacy <i>low</i> • Special Manipulation for Administration: do not crush tablet	
	Disposal / Spills	• Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: n/a
NIOSH Supplemental Information: <i>N/A</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Does not require additional manipulation for administration; will comply with USP 800 recommendation for preparation</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
esterified estrogens and methyltestosterone (Estratest HS) PO [Bulk ⇒ Packager]	Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation <i>Exposure Risk:</i> low	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX gloves, wash hands after handling • Receiving from Distributor: Standard • Pharmacy Storage Area: CSM • Packaging/Reconstitution Location: Repacking area • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Admin. <i>Exposure Risk:</i> low	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- RX Destroyer, packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a
NIOSH Supplemental Information: N/A	
Reason for exemption of USP<800> Containment Requirements: <i>Not Specified</i>	

estradiol (Estrace) PO [Bulk ⇒ Packager]	Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation <i>Exposure Risk:</i> minimal	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX gloves, wash hands after handling • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: Repackaging area • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Admin. <i>Exposure Risk:</i> low	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a
NIOSH Supplemental Information: <i>BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Not Specified</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
estradiol (Alora, Climara, Esclim, Estraderm, Menostar, Minivelle, Vivelle, Vivelle-Dot) Topical Patch [UD ⇒ UD]	Non - Antineoplastic
Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: No	
Transport • Transport (dose is placed inside a plastic sealable bag): Standard	
Nursing: Storage / Admin. • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: No • Closed System Storage Device: No Exposure Risk: • Manipulation of Dosage Form: n/a <i>low</i> • Special Manipulation for Administration: n/a	
Disposal / Spills • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a	
NIOSH Supplemental Information: <i>BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Not Specified</i>	

estradiol (Estrace, Estragyn) Topical Gel / Cream [Bulk ⇒ Bulk]	Non - Antineoplastic
Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: No	
Transport • Transport (dose is placed inside a plastic sealable bag): Standard	
Nursing: Storage / Admin. • Handling/administration PPE Requirements: Double CX gloves • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: No • Closed System Storage Device: No Exposure Risk: • Manipulation of Dosage Form: n/a <i>low</i> • Special Manipulation for Administration: n/a	
Disposal / Spills • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a	
NIOSH Supplemental Information: <i>BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Not Specified</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
estrogens, conjugated (Premarin) IV [n/a]	
Pharmacy: Receiving / Storage / Preparation Exposure Risk: <i>low</i>	Non - Antineoplastic <ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX glove, gown and CSTD • Receiving from Distributor: Standard • Pharmacy Storage Area: Refrigerator • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room Required: Med Prep Area with Immediate Use Preparation standards • Omnicell load: No
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Double Bag; single CX gloves
Nursing: Storage / Admin. Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Double CX gloves and gown; Use of CSTD • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes • Manipulation of Dosage Form: n/a • Special Manipulation for Administration: n/a
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace/packaging- yellow bin • Disposal of Used PPE: yellow bin • Spill management: Wear CX gloves, items used to clean up spill should be placed in a sealed bag and put in blue bin
NIOSH Supplemental Information: <i>BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk</i>	
Reason for exemption of USP<800> Containment Requirements: <i>NIOSH recommends PPE + CSTD for preparation. PPE + CSTD requires for administration. Pregnancy Category X. Risks are related to systemic absorption.</i>	

estrogens, conjugated (Cenestin, Enjuvia, Premarin) PO [Bulk ⇒ Packager]	Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX gloves, wash hands after handling • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: Repackaging area • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Admin. Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: yellow bin • Spill management: n/a
NIOSH Supplemental Information: <i>BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Not Specified</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
estrogens, esterified (Menest) PO [Bulk ⇒ Packager]		Non - Antineoplastic
Pharmacy: <ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX gloves, wash hands after handling 		
Receiving / Storage / Preparation <ul style="list-style-type: none"> • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: Repackaging area 		
Exposure Risk: <i>minimal</i> <ul style="list-style-type: none"> • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: No 		
Transport <ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 		
Nursing: Storage / Admin. <ul style="list-style-type: none"> • Handling/administration PPE Requirements: Double CX gloves and gown; Use of CSTD • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes 		
Exposure Risk: <i>low</i> <ul style="list-style-type: none"> • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a 		
Disposal / Spills <ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a 		
NIOSH Supplemental Information: <i>BBW for malignant neoplasms; increased risk of endometrial, ovarian and breast cancer; in laboratory studies, increased frequency of carcinomas of breast, uterus, cervix, vagina, testis, and liver; present in breast milk</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Not Specified</i>		

exemestane (Aromasin) PO [Bulk ⇒ Blister UD]		Antineoplastic
Pharmacy: <ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Double CX gloves, gown 		
Receiving / Storage / Preparation <ul style="list-style-type: none"> • Receiving from Distributor: Designated area/ CX gloves • Pharmacy Storage Area: Hazardous • Packaging/Reconstitution Location: Repackaging area 		
Exposure Risk: <i>low</i> <ul style="list-style-type: none"> • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: No 		
Transport <ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 		
Nursing: Storage / Admin. <ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes 		
Exposure Risk: <i>low</i> <ul style="list-style-type: none"> • Manipulation of Dosage Form: Done in Pharmacy • Special Manipulation for Administration: do not crush tablet 		
Disposal / Spills <ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: n/a 		
NIOSH Supplemental Information: <i>N/A</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Does not require additional manipulation for administration; will comply with USP 800 recommendation for preparation</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
F	finasteride (Propecia, Proscar) PO [UD ⇒ UD]	Reproductive Risk
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omniceil load: Yes 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Single CX gloves, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell Signage on Patient Door Required: No Closed System Storage Device: No Manipulation of Dosage Form: Standard Special Manipulation for Administration: Do not handle while pregnant 	
Exposure Risk: <i>low</i>		
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposol of Used PPE: trash bin (inside plastic bag) Spill management: n/a 	
NIOSH Supplemental Information: <i>Women should not handle crushed or broken finasteride tablets when they are pregnant or maybecome pregnant, due to potential risks to a male fetus</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

fluconazole (Diflucan) IV [n/a]		Reproductive Risk
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: n/a Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Required: Med Prep Area with Immediate Use Preparation standards Omniceil load: Yes 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Single CX glove Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell Signage on Patient Door Required: No Closed System Storage Device: No Manipulation of Dosage Form: n/a Special Manipulation for Administration: n/a 	
Exposure Risk: <i>low</i>		
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposol of Used PPE: trash bin (inside plastic bag) Spill management: Wear CX gloves, items used to clean up spill should be placed in a sealed bag and put in blue bin 	
NIOSH Supplemental Information: <i>case reports describe congenital abnormalities in infants exposed in utero to maternal fluconazole (400-800mg/d) during most or all of the 1st trimester, similar to those seen in animal studies</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Preg Category C. Risks are related to systemic absorption. For skin contact, remove contaminated clothing, flush area with large amounts of water and soap.</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
fluconazole (Diflucan) PO [UD ⇒ UD]	Reproductive Risk
<p>Pharmacy: • Handling/preparation PPE Requirements: n/a</p> <p>Receiving / Storage / Preparation • Receiving from Distributor: Standard</p> <p>• Pharmacy Storage Area: Carousel</p> <p>Preparation • Packaging/Reconstitution Location: n/a</p> <p><i>Exposure Risk:</i> • Compounding (Non-Sterile/Sterile) Location: n/a</p> <p><i>minimal</i> • Omnicell load: Yes</p>	
<p>Transport • Transport (dose is placed inside a plastic sealable bag): Standard</p>	
<p>Nursing: • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling</p> <p>Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell</p> <p>• Signage on Patient Door Required: No</p> <p><i>Exposure Risk:</i> • Closed System Storage Device: No</p> <p><i>low</i> • Manipulation of Dosage Form: Standard</p> <p>• Special Manipulation for Administration: do not open capsule</p>	
<p>Disposal / Spills • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash</p> <p>• Disposal of Used PPE: trash bin (inside plastic bag)</p> <p>• Spill management: n/a</p>	
<p>NIOSH Supplemental Information: <i>case reports describe congenital abnormalities in infants exposed in utero to maternal fluconazole (400-800mg/d) during most or all of the 1st trimester, similar to those seen in animal studies</i></p>	
<p>Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i></p>	

fosphenytoin (Cerebyx) IV [n/a]	Non - Antineoplastic
<p>Pharmacy: • Handling/preparation PPE Requirements: Single CX glove, gown, and CSTD</p> <p>Receiving / Storage / Preparation • Receiving from Distributor: Standard</p> <p>• Pharmacy Storage Area: IV CSTD Area</p> <p>Preparation • Packaging/Reconstitution Location: n/a</p> <p><i>Exposure Risk:</i> • Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room</p> <p><i>low</i> Required: Med Prep Area with Immediate Use Preparation standards</p> <p>• Omnicell load: No</p>	
<p>Transport • Transport (dose is placed inside a plastic sealable bag): Standard</p>	
<p>Nursing: • Handling/administration PPE Requirements: Single CX glove, gown, use of CSTD</p> <p>Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Omnicell</p> <p>• Signage on Patient Door Required: Yes</p> <p><i>Exposure Risk:</i> • Closed System Storage Device: Yes</p> <p><i>moderate</i> • Manipulation of Dosage Form: n/a</p> <p>• Special Manipulation for Administration: n/a</p>	
<p>Disposal / Spills • Disposal of Drug Waste: Full- black bin</p> <p>Trace- yellow bin</p> <p>• Disposal of Used PPE: yellow bin</p> <p>• Spill management: Manage like antineoplastic agents</p>	
<p>NIOSH Supplemental Information: <i>IARC Group 1 carcinogen; NTP</i></p>	
<p>Reason for exemption of USP<800> Containment Requirements: <i>Preg Category D. No NIOSH requirements but is highest Group for carcinogen to humans; likely only by systemic absorption. For skin contact, remove contaminated clothing, flush area with large amounts of water and soap.</i></p>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
G	ganciclovir (Cytovene) IV [n/a]	Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation <i>Exposure Risk: medium</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Double CX gloves, gown, CSTD • Receiving from Distributor: Standard • Pharmacy Storage Area: Chemo • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: Ideal: Negative pressure room- CACI Required: Med Prep Area with Immediate Use Preparation standards • Omnicell load: No 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Transport container, single CX gloves 	
Nursing: Storage / Admin. <i>Exposure Risk: medium</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Double CX gloves, gown, use of CSTD • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes • Manipulation of Dosage Form: n/a • Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: Manage like antineoplastic agents 	
NIOSH Supplemental Information: <i>in animal studies - carcinogenic, tetatogenic and caused aspermatogenesis; mfg instructions - handle according to guidelines issued for antineoplastic drugs</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Preg Category C. Avoid direct contact of the skin or mucous membranes with CYTOVENE-IV solutions. If such contact occurs, wash thoroughly with soap and water; rinse eyes thoroughly with plain water.</i>		

ganciclovir (Zirgan) OPTH [UD ⇒ UD]		Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation <i>Exposure Risk: minimal</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: No 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin. <i>Exposure Risk: low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Double CX gloves and gown • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: 	
NIOSH Supplemental Information: <i>N/A</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Not Specified</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
H	hydroxyurea (Droxia, Hydrea, Siklos) PO [UD ⇒ UD]	Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Designated area/ CX gloves Pharmacy Storage Area: Hazardous Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omniceil load: No 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Signage on Patient Door Required: Yes 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Closed System Storage Device: Yes Manipulation of Dosage Form: Done in Pharmacy Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- black bin, trace- yellow bin Disposal of Used PPE: yellow bin Spill management: n/a 	
NIOSH Supplemental Information: <i>special warning on handling bottles and capsules</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
L	leflunomide (Arava) PO [Bulk ⇒ Packager]	Non - Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: do not handle while pregnant; single CX gloves 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: Repacking area 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omniceil load: Yes 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Single CX gloves, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell Signage on Patient Door Required: No 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Closed System Storage Device: No Manipulation of Dosage Form: Standard Special Manipulation for Administration: do not handle while pregnant 	
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposal of Used PPE: trash bin (inside plastic bag) Spill management: n/a 	
NIOSH Supplemental Information: <i>Teratogenic in lab studies at 1/10 human dose, marked postnatal survival at 1/100 HD; severe liver injury reported in patients; carcinogenicity observed at doses below HD</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Minimal manipulation for dispensing. Does not require additional manipulation for administering.</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
letrozole (Femara) PO [UD ⇒ UD]		Antineoplastic
Pharmacy: Receiving / Storage / Preparation Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a • Receiving from Distributor: Designated area/ CX gloves • Pharmacy Storage Area: Hazardous • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin. Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes • Manipulation of Dosage Form: Done in Pharmacy • Special Manipulation for Administration: do not crush tablet 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: n/a 	
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

M	medroxyPROGESTERone (Provera) PO [Bulk ⇒ Packager]	Non - Antineoplastic
	Pharmacy: Receiving / Storage / Preparation Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX gloves, wash hands after handling • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: Repacking area • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: No
	Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard
	Nursing: Storage / Admin. Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a
	Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a
	NIOSH Supplemental Information: N/A	
	Reason for exemption of USP<800> Containment Requirements: <i>Minimal manipulation for dispensing. Does not require additional manipulation for administering.</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
medroxyPROGESTERone (Depo-Provera) IM [Vial ⇒ Vial]	Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation <i>Exposure Risk:</i> <i>minimal</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Admin. <i>Exposure Risk:</i> <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Double CX gloves, gown, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: n/a • Special Manipulation for Administration: n/a
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace/packaging- yellow bin • Disposal of Used PPE: yellow bin • Spill management: Wear CX gloves, items used to clean up spill should be placed in a sealed bag and put in blue bin
NIOSH Supplemental Information: N/A	
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form for dispensing, product is drawn up by nursing on unit, proper protections in place for administration</i>	

megestrol (Megace) PO [UD ⇒ UD]	Antineoplastic
Pharmacy: Receiving / Storage / Preparation <i>Exposure Risk:</i> <i>minimal</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a • Receiving from Distributor: Designated area/ CX gloves • Pharmacy Storage Area: Hazardous • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Admin. <i>Exposure Risk:</i> <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes • Manipulation of Dosage Form: Tablet crushed via RxCrush. Soln to be drawn up by nursing at bedside • Special Manipulation for Administration: n/a
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: n/a
NIOSH Supplemental Information: <i>Nursing should be discontinued if megestrol is required. Women at risk of pregnancy should avoid exposure</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
mercaptopurine (Purintehol, Purixan) PO [Bulk ⇒ Blister UD]	Antineoplastic
<p>Pharmacy: • Handling/preparation PPE Requirements: Double CX gloves, gown</p> <p>Receiving / Storage / Preparation • Receiving from Distributor: Designated area/ CX gloves</p> <p>• Pharmacy Storage Area: Hazardous</p> <p>• Packaging/Reconstitution Location: Repackaging area</p> <p>Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a</p> <p><i>low</i> • Omnicell load: No</p>	
<p>Transport • Transport (dose is placed inside a plastic sealable bag): Standard</p>	
<p>Nursing: • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling</p> <p>Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer</p> <p>• Signage on Patient Door Required: Yes</p> <p>Exposure Risk: • Closed System Storage Device: Yes</p> <p><i>low</i> • Manipulation of Dosage Form: Done in Pharmacy</p> <p>• Special Manipulation for Administration: n/a</p>	
<p>Disposal / Spills • Disposal of Drug Waste: Full- black bin, trace- yellow bin</p> <p>• Disposal of Used PPE: yellow bin</p> <p>• Spill management: n/a</p>	
<p>NIOSH Supplemental Information: N/A</p>	
<p>Reason for exemption of USP<800> Containment Requirements: <i>Does not require additional manipulation for administration; will comply with USP 800 recommendation for preparation</i></p>	

methIMazole (Tapazole) PO [UD ⇒ UD]	Non - Antineoplastic
<p>Pharmacy: • Handling/preparation PPE Requirements: n/a</p> <p>Receiving / Storage / Preparation • Receiving from Distributor: Standard</p> <p>• Pharmacy Storage Area: Carousel</p> <p>• Packaging/Reconstitution Location: n/a</p> <p>Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a</p> <p><i>minimal</i> • Omnicell load: No</p>	
<p>Transport • Transport (dose is placed inside a plastic sealable bag): Standard</p>	
<p>Nursing: • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling</p> <p>Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer</p> <p>• Signage on Patient Door Required: No</p> <p>Exposure Risk: • Closed System Storage Device: No</p> <p><i>low</i> • Manipulation of Dosage Form: Standard</p> <p>• Special Manipulation for Administration: n/a</p>	
<p>Disposal / Spills • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash</p> <p>• Disposal of Used PPE: trash bin (inside plastic bag)</p> <p>• Spill management: n/a</p>	
<p>NIOSH Supplemental Information: <i>appears in human breast milk</i></p>	
<p>Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i></p>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
methotrexate (Otrexup, Rasuvo, Rheumatrex, Trexall, Xatmep) PO [UD ⇒ UD]		Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Designated area/ CX gloves Pharmacy Storage Area: Hazardous Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omniceil load: No 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Single CX gloves, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Signage on Patient Door Required: Yes Closed System Storage Device: Yes 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Manipulation of Dosage Form: Done in Pharmacy Special Manipulation for Administration: do not crush tablet 	
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- black bin, trace- yellow bin Disposal of Used PPE: yellow bin Spill management: n/a 	
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

Methotrexate (Trexall) IM [Vial ⇒]		Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: Single CX glove, gown, and CSTD (as dosage form allows) 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Designated area/ CX gloves Pharmacy Storage Area: Hazardous, Chemo zip locking bag Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>moderate</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: Required: Med Prep Area with Immediate Use Preparation standards Omniceil load: No 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Double bag Single CX gloves 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Double CX glove, gown Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy Signage on Patient Door Required: Yes Closed System Storage Device: Yes 	
Exposure Risk: <i>moderate</i>	<ul style="list-style-type: none"> Manipulation of Dosage Form: 1 vial per syringe - label accordingly Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- black bin Trace- yellow bin Disposal of Used PPE: Yellow bin Spill management: Wear CX gloves; items used to clean up spill should be placed in a sealed bag and put in yellow bin 	
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>The act of drawing up an IM dose of methotrexate and giving it immediately is considered administration.</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
methylergonovine (Methergine) PO [UD ⇒ UD]		Reproductive Risk
Pharmacy:	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a 	
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

methylergonovine (Methergine) IM [UD ⇒ UD]		Reproductive Risk
Pharmacy:	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> • Receiving from Distributor: Standard • Pharmacy Storage Area: Refrigerator • Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Double CX gloves, gown • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No 	
Exposure Risk: <i>medium</i>	<ul style="list-style-type: none"> • Manipulation of Dosage Form: n/a • Special Manipulation for Administration: Use Negative Pressure Technique when pulling up dose 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: yellow bin • Spill management: Wear CX gloves, items used to clean up spill should be placed in a sealed bag and put in blue bin 	
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>Following USP 800 recommendations</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
miSOPROStol (Cytotec) PO [UD ⇒ UD]		Reproductive Risk
Pharmacy: Receiving / Storage / Preparation Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin. Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: if tablet is split must add PPE of gown and mask 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a 	
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. May cause infertility. May cause harm to unborn child.</i>		

mitoMYcin (Mitosol) OPTH [UD ⇒ UD]		Antineoplastic
Pharmacy: Receiving / Storage / Preparation Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a • Receiving from Distributor: Designated area/ CX gloves • Pharmacy Storage Area: Chemo • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: No 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Transport container, single CX gloves 	
Nursing: Storage / Admin. Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Double CX gloves and gown • Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes • Manipulation of Dosage Form: n/a • Special Manipulation for Administration: 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: Manage like antineoplastic agents 	
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>Not Specified</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
mycophenolate mofetil (Cellcept) PO [UD ⇒ UD]	Non - Antineoplastic
Pharmacy: <ul style="list-style-type: none"> Handling/preparation PPE Requirements: do not handle while pregnant; single CX gloves 	
Receiving / Storage / Preparation <ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i> <ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omniceil load: Yes 	
Transport <ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin. <ul style="list-style-type: none"> Handling/administration PPE Requirements: do not open capsule, do not handle while pregnant Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell Signage on Patient Door Required: No Closed System Storage Device: No 	
Exposure Risk: <i>low</i> <ul style="list-style-type: none"> Manipulation of Dosage Form: Standard Special Manipulation for Administration: do not open capsule, do not handle while pregnant 	
Disposal / Spills <ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposal of Used PPE: trash bin (inside plastic bag) Spill management: n/a 	
NIOSH Supplemental Information: <i>BBW for embryo of fetal toxicity, malignancies, and serious infections, increased risk of first-trimester pregnancy loss and increased risk of congenital malformations; Special Warning: Tablets should not be crushed and capsules should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membrane of the powder contained in capsules and oral suspension. If such contact occurs, wash thoroughly with soap and water, rinse eyes with plain water</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
mycophenolic acid (Myfortic) PO [Bulk ⇒ Packager]	Non - Antineoplastic
Pharmacy: <ul style="list-style-type: none"> Handling/preparation PPE Requirements: Single CX gloves, wash hands after handling 	
Receiving / Storage / Preparation <ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: Repackaging area 	
Exposure Risk: <i>low</i> <ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omniceil load: No 	
Transport <ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin. <ul style="list-style-type: none"> Handling/administration PPE Requirements: Single CX gloves, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Signage on Patient Door Required: No Closed System Storage Device: No 	
Exposure Risk: <i>low</i> <ul style="list-style-type: none"> Manipulation of Dosage Form: Standard Special Manipulation for Administration: n/a 	
Disposal / Spills <ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposal of Used PPE: trash bin (inside plastic bag) Spill management: n/a 	
NIOSH Supplemental Information: <i>BBW for first trimester pregnancy loss and increased risk of congenital malformations, BBW for lymphomas and other malignancies; genotoxic in vitro and in vivo</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Minimal manipulation for dispensing. Does not require additional manipulation for administering.</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
O	OXcarbazepine (Oxtellar XR, Trileptal) PO [UD ⇒ UD]	Non - Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell Signage on Patient Door Required: No 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Closed System Storage Device: No Manipulation of Dosage Form: Standard Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposal of Used PPE: trash bin (inside plastic bag) Spill management: n/a 	
NIOSH Supplemental Information: <i>Tumors observed in lab studies at 1/10 MRHD</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

oxytocin (Pitocin) IV [n/a]		Reproductive Risk
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: Single CX gloves, gown 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room Required: Med Prep Area with Immediate Use Preparation standards Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Single CX gloves, gown, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell Signage on Patient Door Required: No 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Closed System Storage Device: No Manipulation of Dosage Form: n/a Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposal of Used PPE: trash bin (inside plastic bag) Spill management: Wear CX gloves, items used to clean up spill should be placed in a sealed bag and put in blue bin 	
NIOSH Supplemental Information: <i>Harzardous only of women in 3rd trimester</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Not Specified</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
P	pamidronate (Aredia) IV [n/a]	Reproductive Risk
Pharmacy: Receiving / Storage / Preparation <i>Exposure Risk:</i> low	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX glove, gown and CSTD. • Do not prepare if pregnant. • Receiving from Distributor: Standard • Pharmacy Storage Area: IV area • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room Required: Med Prep Area with Immediate Use Preparation standards • Omnicell load: No 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin. <i>Exposure Risk:</i> medium	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, gown • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: n/a • Special Manipulation for Administration: Do not handle while pregnant 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: Wear CX gloves, items used to clean up spill should be placed in a sealed bag and put in blue bin 	
NIOSH Supplemental Information: <i>Embryo-fetal toxicities at doses below recommended human doses</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Preg Category D. Impervious gloves and gown are recommended in MSDS.</i>		

PARoxetine (Paxil) PO [UD ⇒ UD]		Reproductive Risk
Pharmacy: Receiving / Storage / Preparation <i>Exposure Risk:</i> minimal	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin. <i>Exposure Risk:</i> low	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: do not crush tablet 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a 	
NIOSH Supplemental Information: <i>Increased risk of congenital abnormalities when taken in first trimester; complications in pregnancy when taken in 3rd trimester</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
phenytoin (Dilantin) IV [n/a]		Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation <i>Exposure Risk:</i> low	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX glove, gown, and CSTD • Receiving from Distributor: Standard • Pharmacy Storage Area: IV CSTD Area • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room Required: Med Prep Area with Immediate Use Preparation standards • Omnicell load: No 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Double bag, single CX gloves 	
Nursing: Storage / Admin. <i>Exposure Risk:</i> medium	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX glove, gown, use of CSTD • Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes • Manipulation of Dosage Form: n/a • Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: Manage like antineoplastic agents 	
NIOSH Supplemental Information: IARC Group 1 carcinogen; NTP		
Reason for exemption of USP<800> Containment Requirements: Preg Category D. No NIOSH requirements but is highest Group for carcinogen to humans; likely only by systemic absorption. For skin contact, remove contaminated clothing, flush area with large amounts of water and soap.		

phenytoin (Dilantin, Phenytek) PO [UD ⇒ UD]		Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation <i>Exposure Risk:</i> minimal	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin. <i>Exposure Risk:</i> low	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace/packaging- yellow bin • Disposal of Used PPE: yellow bin • Spill management: n/a 	
NIOSH Supplemental Information: IARC Group 1 carcinogen; NTP		
Reason for exemption of USP<800> Containment Requirements: Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
progesterone (Endometrin, Prometrium) PO [Bulk ⇒ Packager]		Non - Antineoplastic
Pharmacy:	• Handling/preparation PPE Requirements: Single CX gloves, wash hands after handling	
Receiving /	• Receiving from Distributor: Standard	
Storage /	• Pharmacy Storage Area: Carousel	
Preparation	• Packaging/Reconstitution Location: Repackage area	
Exposure Risk:	• Compounding (Non-Sterile/Sterile) Location: n/a	
<i>low</i>	• Omnicell load: Yes	
Transport	• Transport (dose is placed inside a plastic sealable bag): Standard	
Nursing:	• Handling/administration PPE Requirements: Single CX gloves, wash hands after handling	
Storage /	• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell	
Admin.	• Signage on Patient Door Required: No	
Exposure Risk:	• Closed System Storage Device: No	
<i>low</i>	• Manipulation of Dosage Form: Standard	
	• Special Manipulation for Administration: n/a	
Disposal /	• Disposal of Drug Waste: Full- blue bin, trace/packaging- trash	
Spills	• Disposal of Used PPE: trash bin (inside plastic bag)	
	• Spill management: n/a	
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>Minimal manipulation for dispensing. Does not require additional manipulation for administering.</i>		

propylthiouracil (PTU) PO [UD ⇒ UD]		Non - Antineoplastic
Pharmacy:	• Handling/preparation PPE Requirements: n/a	
Receiving /	• Receiving from Distributor: Standard	
Storage /	• Pharmacy Storage Area: Carousel	
Preparation	• Packaging/Reconstitution Location: n/a	
Exposure Risk:	• Compounding (Non-Sterile/Sterile) Location: n/a	
<i>minimal</i>	• Omnicell load: No	
Transport	• Transport (dose is placed inside a plastic sealable bag): Standard	
Nursing:	• Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling	
Storage /	• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell	
Admin.	• Signage on Patient Door Required: No	
Exposure Risk:	• Closed System Storage Device: No	
<i>low</i>	• Manipulation of Dosage Form: Standard	
	• Special Manipulation for Administration: n/a	
Disposal /	• Disposal of Drug Waste: Full- blue bin, trace/packaging- trash	
Spills	• Disposal of Used PPE: trash bin (inside plastic bag)	
	• Spill management: n/a	
NIOSH Supplemental Information: IARC Group 2B; NTP***		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

USP <800> Hazardous Drugs Assessment of Risk

	generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
R	raloxifene (Evista) PO [UD ⇒ UD]	Non - Antineoplastic
	Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: No	
	Transport • Transport (dose is placed inside a plastic sealable bag): Standard	
	Nursing: Storage / Admin. • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: No • Closed System Storage Device: No Exposure Risk: • Manipulation of Dosage Form: Standard <i>low</i> • Special Manipulation for Administration: n/a	
	Disposal / Spills • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a	
	NIOSH Supplemental Information: <i>Abortion and developmental abnormalities seen at low doses in lab studies, evidence of tumors at low doses</i>	
	Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

S	spironolactone (Aldactone) PO [UD ⇒ UD]	Non - Antineoplastic
	Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: Yes	
	Transport • Transport (dose is placed inside a plastic sealable bag): Standard	
	Nursing: Storage / Admin. • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No Exposure Risk: • Closed System Storage Device: No <i>low</i> • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a	
	Disposal / Spills • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a	
	NIOSH Supplemental Information: <i>BBW for tumorigenicity in lab studies</i>	
	Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
T	tacrolimus (Prograf) PO [UD ⇒ UD]	Non - Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a 	
NIOSH Supplemental Information: <i>Increased risk of lymphomas and other malignancies; reproductive effects seen in lab studies below MRHD; excreted in breast milk</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

tamoxifen (Nolvadex, Soltamox) PO [UD ⇒ UD]		Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> • Receiving from Distributor: Designated area/ CX gloves • Pharmacy Storage Area: Hazardous • Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: Yes 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Closed System Storage Device: Yes • Manipulation of Dosage Form: Done in Pharmacy • Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: n/a 	
NIOSH Supplemental Information: <i>IARC Group 1 carcinogen; NTP***</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
temazepam (Restoril) PO [UD ⇒ UD]	
Non - Antineoplastic	
Pharmacy: Receiving / Storage / Preparation Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: n/a • Receiving from Distributor: Standard • Pharmacy Storage Area: CSM • Packaging/Reconstitution Location: n/a • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Admin. Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- RX Destroyer, packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a
NIOSH Supplemental Information: <i>increased risk of congenital malformations associated with treatment during 1st trimester</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

temazepam (Restoril) PO [Bulk ⇒ UD]	Non - Antineoplastic
Pharmacy: Receiving / Storage / Preparation Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> • Handling/preparation PPE Requirements: Single CX gloves, wash hands after handling • Receiving from Distributor: Standard • Pharmacy Storage Area: CSM • Packaging/Reconstitution Location: Repackage area • Compounding (Non-Sterile/Sterile) Location: n/a • Omnicell load: Yes
Transport	<ul style="list-style-type: none"> • Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: Storage / Admin. Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> • Handling/administration PPE Requirements: Single CX gloves, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No • Closed System Storage Device: No • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a
Disposal / Spills	<ul style="list-style-type: none"> • Disposal of Drug Waste: Full- RX Destroyer, packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a
NIOSH Supplemental Information: <i>increased risk of congenital malformations associated with treatment during 1st trimester</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Minimal manipulation for dispensing. Does not require additional manipulation for administering.</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
testosterone (Depo-T) IM [n/a]	Reproductive Risk
Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: CSM • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: No	
Transport • Transport (dose is placed inside a plastic sealable bag): Standard	
Nursing: Storage / Admin. • Handling/administration PPE Requirements: Single CX gloves, gown, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy • Signage on Patient Door Required: No • Closed System Storage Device: No Exposure Risk: • Manipulation of Dosage Form: n/a <i>low</i> • Special Manipulation for Administration: n/a	
Disposal / Spills • Disposal of Drug Waste: Full- RX Destroyer, packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: Wear CX gloves, items used to clean up spill should be placed in a sealed bag and put in blue bin	
NIOSH Supplemental Information: <i>Children should avoid contact with unwashed or unclothed application sites on skin</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Not Specified</i>	

topiramate (Topamax) PO [UD ⇒ UD]	Reproductive Risk
Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: Yes	
Transport • Transport (dose is placed inside a plastic sealable bag): Standard	
Nursing: Storage / Admin. • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No Exposure Risk: • Closed System Storage Device: No <i>low</i> • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a	
Disposal / Spills • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a	
NIOSH Supplemental Information: <i>N/A</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
V	valGANCiclovir (Valcyte) PO [UD ⇒ UD]	Non - Antineoplastic
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omniceil load: No 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Signage on Patient Door Required: No 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Closed System Storage Device: No Manipulation of Dosage Form: Standard Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposol of Used PPE: trash bin (inside plastic bag) Spill management: n/a 	
NIOSH Supplemental Information: N/A		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

valproic acid (Depacon) IV [n/a]		Reproductive Risk
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: Single CX glove, gown, and CSTD 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Do not prepare if pregnant. Receiving from Distributor: Standard Pharmacy Storage Area: IV CSTD Area Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room Required: Med Prep Area with Immediate Use Preparation standards Omniceil load: No 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Double bag, single CX gloves 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Single CX glove, gown, use of CSTD Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy Signage on Patient Door Required: Yes 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Closed System Storage Device: Yes Manipulation of Dosage Form: n/a Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- black bin, trace- yellow bin Disposol of Used PPE: yellow bin Spill management: Manage like antineoplastic agents 	
NIOSH Supplemental Information: <i>BBW for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Preg Category D. Risks are related to systemic absorption. Skin contact - wash immediately with soap and water.</i>		

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
valproic acid (Depakene, Depakote) PO [UD ⇒ UD]	Reproductive Risk
Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: Yes	
Transport	• Transport (dose is placed inside a plastic sealable bag): Standard
Nursing: • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No Exposure Risk: • Closed System Storage Device: No <i>low</i> • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a	
Disposal / Spills	• Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a
NIOSH Supplemental Information: <i>BBW for teratogenicity; congenital malformations, including neural tube defects; teratogenic in multiple species</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

voriconazole (Vfend) IV [n/a]	Reproductive Risk
Pharmacy: • Handling/preparation PPE Requirements: Double CX gloves, gown, CSTD Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: IV CSTD Area • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room <i>low</i> Required: Med Prep Area with Immediate Use Preparation standards • Omnicell load: No	
Transport	• Transport (dose is placed inside a plastic sealable bag): Double bag, single CX gloves
Nursing: • Handling/administration PPE Requirements: Single CX glove, gown, use of CSTD Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Picked up from Pharmacy • Signage on Patient Door Required: Yes Exposure Risk: • Closed System Storage Device: Yes <i>low</i> • Manipulation of Dosage Form: n/a • Special Manipulation for Administration: n/a	
Disposal / Spills	• Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: Manage like antineoplastic agents
NIOSH Supplemental Information: <i>N/A</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Preg Category D. Release to the environment should be minimized per MSDS.</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
voriconazole (Vfend) PO [UD ⇒ UD]	Reproductive Risk
Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: No	
Transport • Transport (dose is placed inside a plastic sealable bag): Standard	
Nursing: • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: No Exposure Risk: • Closed System Storage Device: No <i>low</i> • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a	
Disposal / Spills • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a	
NIOSH Supplemental Information: N/A	
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

W	warfarin (Coumadin, Jantoven) PO [UD ⇒ UD]	Reproductive Risk
	Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: Yes	
	Transport • Transport (dose is placed inside a plastic sealable bag): Standard	
	Nursing: • Handling/administration PPE Requirements: Mouth - Single pair of CX approved gloves. Tube - double CX gloves and gown. Wash hands after handling Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: No Exposure Risk: • Closed System Storage Device: No <i>low</i> • Manipulation of Dosage Form: Standard • Special Manipulation for Administration: n/a	
	Disposal / Spills • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash • Disposal of Used PPE: trash bin (inside plastic bag) • Spill management: n/a	
	NIOSH Supplemental Information: N/A	
	Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]		NIOSH Group
Z	ziprasidone (Geodon) PO [UD ⇒ UD]	Reproductive Risk
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>minimal</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omnicell load: No 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Single pair of CX approved gloves Wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer Signage on Patient Door Required: No 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Closed System Storage Device: No Manipulation of Dosage Form: Standard Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposal of Used PPE: trash bin (inside plastic bag) Spill management: n/a 	
NIOSH Supplemental Information: <i>Developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses; an increase in the number of pups born dead and a decrease in postnatal survival at less than MRHD</i>		
Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i>		

ziprasidone (Geodon) IM [n/a]		Reproductive Risk
Pharmacy:	<ul style="list-style-type: none"> Handling/preparation PPE Requirements: n/a 	
Receiving / Storage / Preparation	<ul style="list-style-type: none"> Receiving from Distributor: Standard Pharmacy Storage Area: Carousel Packaging/Reconstitution Location: n/a 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Compounding (Non-Sterile/Sterile) Location: n/a Omnicell load: Yes 	
Transport	<ul style="list-style-type: none"> Transport (dose is placed inside a plastic sealable bag): Standard 	
Nursing: Storage / Admin.	<ul style="list-style-type: none"> Handling/administration PPE Requirements: Single CX glove, gown Wash hands after handling Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell Signage on Patient Door Required: No 	
Exposure Risk: <i>low</i>	<ul style="list-style-type: none"> Closed System Storage Device: No Manipulation of Dosage Form: n/a Special Manipulation for Administration: n/a 	
Disposal / Spills	<ul style="list-style-type: none"> Disposal of Drug Waste: Full- blue bin, trace/packaging- trash Disposal of Used PPE: trash bin (inside plastic bag) Spill management: Wear CX gloves, items used to clean up spill should be placed in a sealed bag and put in blue bin 	
NIOSH Supplemental Information: <i>Developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses; an increase in the number of pups born dead and a decrease in postnatal survival at less than MRHD</i>		

USP <800> Hazardous Drugs Assessment of Risk

Reason for exemption of USP<800> Containment Requirements: *Purchased in final dosage form for dispensing, product is drawn up by nursing on unit, proper protections in place for administration. Wash off immediately with plenty of water for at least 15 minutes.*

**This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)*

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
zoledronic acid (Reclast - Ready to hang) IV [n/a]	Reproductive Risk
Pharmacy: • Handling/preparation PPE Requirements: n/a Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: Carousel • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a <i>minimal</i> • Omnicell load: Yes	
Transport • Transport (dose is placed inside a plastic sealable bag): Standard	
Nursing: Storage / Admin. • Handling/administration PPE Requirements: Single CX glove and gown • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes Exposure Risk: • Manipulation of Dosage Form: n/a <i>medium</i> • Special Manipulation for Administration: Do not handle while pregnant	
Disposal / Spills • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: Manage like antineoplastic agents	
NIOSH Supplemental Information: <i>Number of stillbirths increased and survival of neonates decreased in lab studies at low doses</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Preg Category D. For skin contact, remove contaminated clothing, flush area with large amounts of water and soap.</i>	

zoledronic acid (Zometa) IV [n/a]	Reproductive Risk
Pharmacy: • Handling/preparation PPE Requirements: Single CX glove and gown; use of CSTD Do not prepare if pregnant. Receiving / Storage / Preparation • Receiving from Distributor: Standard • Pharmacy Storage Area: IV Room • Packaging/Reconstitution Location: n/a Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: Ideal: Positive pressure room <i>medium</i> Required: Med Prep Area with Immediate Use Preparation standards • Omnicell load: No	
Transport • Transport (dose is placed inside a plastic sealable bag): Standard	
Nursing: Storage / Admin. • Handling/administration PPE Requirements: Single CX glove, gown, use of CSTD • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer • Signage on Patient Door Required: Yes • Closed System Storage Device: Yes Exposure Risk: • Manipulation of Dosage Form: n/a <i>medium</i> • Special Manipulation for Administration: Do not handle while pregnant	
Disposal / Spills • Disposal of Drug Waste: Full- black bin, trace- yellow bin • Disposal of Used PPE: yellow bin • Spill management: Manage like antineoplastic agents	
NIOSH Supplemental Information: <i>Number of stillbirths increased and survival of neonates decreased in lab studies at low doses</i>	
Reason for exemption of USP<800> Containment Requirements: <i>Preg Category D. For skin contact, remove contaminated clothing, flush area with large amounts of water and soap.</i>	

USP <800> Hazardous Drugs Assessment of Risk

generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense]	NIOSH Group
zonisamide (Zonegran) PO [UD ⇒ UD]	Reproductive Risk
<p>Pharmacy: • Handling/preparation PPE Requirements: n/a</p> <p>Receiving / Storage / Preparation • Receiving from Distributor: Standard</p> <p>• Pharmacy Storage Area: Carousel</p> <p>• Packaging/Reconstitution Location: n/a</p> <p>Exposure Risk: • Compounding (Non-Sterile/Sterile) Location: n/a</p> <p><i>minimal</i> • Omnicell load: Yes</p>	
<p>Transport • Transport (dose is placed inside a plastic sealable bag): Standard</p>	
<p>Nursing: • Handling/administration PPE Requirements: PO- Single CX gloves, tube- double CX gloves and gown, wash hands after handling</p> <p>Storage / Admin. • Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer, Omnicell</p> <p>• Signage on Patient Door Required: No</p> <p>Exposure Risk: • Closed System Storage Device: No</p> <p><i>low</i> • Manipulation of Dosage Form: Standard</p> <p>• Special Manipulation for Administration: Do not handle while pregnant</p>	
<p>Disposal / Spills • Disposal of Drug Waste: Full- blue bin, trace/packaging- trash</p> <p>• Disposal of Used PPE: trash bin (inside plastic bag)</p> <p>• Spill management: n/a</p>	
<p>NIOSH Supplemental Information: <i>Teratogenic in multiple miscellaneous animal studies</i></p>	
<p>Reason for exemption of USP<800> Containment Requirements: <i>Purchased in final dosage form; packaged as unit dose. Does not require additional manipulation for dispensing.</i></p>	

USP <800> Hazardous Drugs Assessment of Risk

Brand Name Index

Aldactone - see spironolactone	Alora - see estradiol
Arava - see leflunomide	Aredia - see pamidronate
Arimidex - see anastrozole	Aromasin - see exemestane
Avodart - see dutasteride	Carbatrol - see carbamazepine
Casodex - see bicalutamide	Cellcept - see mycophenolate mofetil
Cenestin - see estrogens, conjugated	Cerebyx - see fosphenytoin
Cervidil - see dinoprostone topical	Climara - see estradiol
Colcrys - see colchicine	Coumadin - see warfarin
Cytotec - see misoprostol	Cytovene - see ganciclovir
Depacon - see valproic acid	Depakene - see valproic acid
Depakote - see valproic acid	Depo-Provera - see medroxyprogesterone
Depo-T - see testosterone	Diflucan - see fluconazole
Dilantin - see phenytoin	Droxia - see hydroxyurea
Endometrin - see progesterone	Enjuvia - see estrogens, conjugated
Esclim - see estradiol	Estrace - see estradiol
Estraderm - see estradiol	Estragyn - see estradiol
Estratest HS - see esterified estrogens and methyltestosterone	Evista - see raloxifene
Femara - see letrozole	Gengraf - see cyclosporine
Geodon - see ziprasidone	Hydrea - see hydroxyurea
Jantoven - see warfarin	Klonopin - see clonazepam
Megace - see megestrol	Menest - see estrogens, esterified
Menostar - see estradiol	Minivelle - see estradiol
Mitigare - see colchicine	Mitosol - see mitomycin
Multaq - see dronedarone	Myfortic - see mycophenolic acid
Neoral - see cyclosporine	Nolvadex - see tamoxifen
Otrexup - see methotrexate	Oxtellar XR - see oxcarbazepine
Paxil - see paroxetine	Phenytek - see phenytoin
Pitocin - see oxytocin	Premarin - see estrogens, conjugated
Prepidil - see dinoprostone topical	Prograf - see tacrolimus
Prometrium - see progesterone	Propecia - see finasteride
Proscar - see finasteride	Prostin E2 - see dinoprostone topical
Provera - see medroxyprogesterone	PTU - see propylthiouracil
Purinethol - see mercaptopurine	Purixan - see mercaptopurine
Rasuvo - see methotrexate	Reclast - see zoledronic acid
Restoril - see temazepam	Rheumatrex - see methotrexate
Sandimmune - see cyclosporine	Siklos - see hydroxyurea
Soltamox - see tamoxifen	Tapazole - see methimazole
Tarceva - see erlotinib	TEGretol - see carbamazepine
Topamax - see topiramate	Trexall - see methotrexate
Trileptal - see oxcarbazepine	Valcyte - see valganciclovir
Vfend - see voriconazole	Vistide - see cidofovir
Vivelle - see estradiol	Vivelle-Dot - see estradiol
Xatmep - see methotrexate	Ziagen - see abacavir
Zirgan - see ganciclovir	Zometa - see zoledronic acid
Zonegran - see zonisamide	